Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 19/20 | 0.67 |
| ▸ | BRAF | P15056 | 10/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | ARAF | P10398 | 1/20 | 0.57 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.57 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30405471 | 1.00 | RAF1 (0.67) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL25984118 | 0.96 | RAF1 (0.65) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL25984145 | 0.94 | RAF1 (0.63) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL25029643 | 0.93 | RAF1 (0.63) | RAF1BRAF | |
| SCHEMBL25281938 | 0.92 | BRAF (0.67) | RAF1BRAF | |
| SCHEMBL30405362 | 0.92 | BRAF (0.67) | RAF1BRAF | |
| SCHEMBL25238127 | 0.90 | RAF1 (0.71) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL30405244 | 0.90 | RAF1 (0.68) | RAF1BRAF | |
| SCHEMBL30405789 | 0.90 | RAF1 (0.71) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL25281315 | 0.90 | RAF1 (0.68) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250235-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-08-07 | — | — | US | disclosed |
| US-12319655-B2 | RAF kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4444429-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| WO-2023108108-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023108108-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230046018-A1 | BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| WO-2021110141-A1 | BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR | 南京明德新药研发有限公司 | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319655-B2 | RAF kinase inhibitors and methods of use thereof | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885PDGFRB 1056/4885 |
| US-20230046018-A1 | BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885PDGFRB 1139/4885 |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885PDGFRB 1056/4885 |
| US-20250250235-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885PDGFRB 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.